Compare Medtronic PLC (MDT) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Xpeng Inc - ADR — how do they compare? Medtronic PLC trades at $82.6 (market cap $106.61B), while Xpeng Inc - ADR trades at $13.17 (market cap $12.96B). The key difference: Medtronic PLC is far larger — about 8.2× Xpeng Inc - ADR's market cap, and Medtronic PLC pays a 3.46% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| MDT | XPEV | |
|---|---|---|
Market Cap | $106.61B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $28.07 |
52-Week Low | $73.75 | $12.09 |
Enterprise Value | $125.36B | $15.07B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
XPEV stock trades at $13.22, down 2.33% on the day, with a neutral technical outlook. The company reported revenue of $76.72 billion in 2025, but net losses persist, though the margin improved to -1.49%. Recent news highlights overseas expansion with the L03 SUV launch in Munich and progress in autonomous driving technology. Analyst consensus is bullish with a $17.00 price target, but cash flow volatility and competitive pressures remain concerns.
The outlook for XPEV hinges on execution of global expansion and new model launches to drive profitability. Investment opportunity lies in market share gains and technology leadership in EVs and AI, but risks include intense competition, reliance on Chinese market dynamics, and ongoing cash burn. The stock offers growth potential if the company can sustain revenue growth and narrow losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
